{
    "nct_id": "NCT06839872",
    "official_title": "BOSS: BTK Inhibitor Optimal Sequencing Study Phase II Open-label Single Arm Trial of Pirtobrutinib in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma After First-line Acalabrutinib Progression",
    "inclusion_criteria": "* Participant must be ≥ 18 at the time of signing the informed consent.\n* Participants must have received acalabrutinib monotherapy as first-line treatment for CLL/SLL, have progressed per the iwCLL Criteria (Hallek et al 2018) and be eligible for second-line treatment by the same criteria.\n* ECOG performance status of 0, 1, or 2.\n* Adequate organ and BM function.\n* Adequate coagulation, defined as aPTT or PTT and PT or INR not greater than 1.5 × ULN.\n* Participants have a clearly defined, documented and accessible start date of their first line acalabrutinib monotherapy for CLL/SLL.\n* Participants are eligible for the acalabrutinib retreatment phase only if they have progressed on pirtobrutinib monotherapy per iwCLL Criteria.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 110 Years",
    "exclusion_criteria": "* Major surgical procedure within 30 days before and not recovered adequately the first dose of study drug.\n* Participants who experienced a major bleeding event or Grade ≥ 3 arrhythmia on prior treatment with a BTK inhibitor.\n* History of bleeding diathesis (eg, hemophilia, von Willebrand disease).\n* History of stroke or intracranial hemorrhage within 6 months before first dose of study drug.\n* Significant cardiovascular disease.\n* History of PML.\n* Any active significant infection.\n* HIV positive\n* Active HBV or HCV infection.\n* Active CNS involvement by lymphoma, leptomeningeal disease, or spinal cord compression.\n* Active auto-immune cytopenia.\n* History of prior or current malignancy.\n* Requires or receiving therapeutic anticoagulation with warfarin or equivalent vitamin K antagonists.\n* Received a live virus vaccination within 28 days of first dose of study drug.\n* Requires treatment with a strong CYP3A inhibitor or inducer. The use of strong CYP3A inhibitors within 1 week or strong CYP3A inducers within 3 weeks of the first dose of study drug is prohibited.",
    "miscellaneous_criteria": ""
}